{"title":"基于证据的缺血性心脏病二级预防。1 .药物治疗的进展和证据;抗血小板药物的当前主题[j]。","authors":"Yoshihisa Nakagawa","doi":"","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":19633,"journal":{"name":"Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine","volume":"106 2","pages":"232-7"},"PeriodicalIF":0.0000,"publicationDate":"2017-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Evidence Based Secondary Prevention of Ischemic Heart Disease. Topics: I. Advances and Evidence of Pharmacotherapy: 5. Current Topics of Antiplatelet Drug].\",\"authors\":\"Yoshihisa Nakagawa\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":19633,\"journal\":{\"name\":\"Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine\",\"volume\":\"106 2\",\"pages\":\"232-7\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
[Evidence Based Secondary Prevention of Ischemic Heart Disease. Topics: I. Advances and Evidence of Pharmacotherapy: 5. Current Topics of Antiplatelet Drug].